Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)
- Poster presentation
- Open Access
Generation of tumor-infiltrating lymphocytes from pancreatic cancer lesions for cellular therapy
Journal for ImmunoTherapy of Cancer volume 2, Article number: P26 (2014)
The generation of T lymphocytes with specific reactivity against autologous tumor is a prerequisite for effective adoptive transfer therapies. Pancreatic cancer-specific lymphocyte cultures from tumor infiltrating lymphocytes (TILs) may represent a viable source of T cells for the biological therapy for patients with pancreatic cancer.
Pancreatic cancer tissue was obtained either by surgery or from biopsy specimens from 16 patients and cultured with cytokines (IL-2, IL-15and IL-21). TIL were expanded using OKT-3 and irradiated allogeneic peripheral blood mononuclear cells (PBMCs). TIL reactivity was gauged for recognition of molecularly defined tumor-associated antigens (TAAs, mesothelin, survivin and NY-ESO-1) by IFNgamma production and intracellular cytokine production (ICS). TCR VB T cell populations were tested by a panel of TCR Vb specific antibodies, along with T cell differentiation and exhaustion markers by flow cytometry.
TIL from 16/16 patients, up to 10e11 cells, could be successfully expanded using IL-2/15/21. 4 week TIL cultures showed up to 90% CD8+ T cells, yet 1/16 TIL cultures exhibited exclusively CD4+ TIL with a CD45RA-CCR7+ phenotype. 12 / 16 of TILs showed preferential expansion of TCR VB families, i.e. 99.3% in Vb13.2 in CD8+ TIL, 77% in VB1, 68.7% in VB22, 64% in VB14 for individual patients. Even biopsy specimens (about 10 mg), yielded at least 1.5 x10e9 CD8 TIL. ICS analysis showed a low frequency (up to 2.5%) of mesothelin, survivin or NY-ESO-1 reactive CD8+ TIL. TIL from a 1/16 patients showed up to 10% NY-ESO-1 specific IFNgamma and TNFalpha production in CD4+ and CD8+ T cells. Tumors from these patients are currently sequenced for mutations and subsequent testing for TIL recognition.
We have optimized methods for the robust and fast generation of TIL from pancreatic cancer lesions, including small biopsy specimens, using a cytokine cocktail of IL-2/IL-15 and IL-21. TIL showed a Th1-cytokine production pattern and a central memory phenotype. A Phase I clinical safety trial at Karolinska is currently prepared for IL-2/15/21-expanded TIL for the cellular therapy for patients with pancreatic cancer.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Meng, Q., Rangelova, E.B., zhenjiang, L. et al. Generation of tumor-infiltrating lymphocytes from pancreatic cancer lesions for cellular therapy. j. immunotherapy cancer 2 (Suppl 3), P26 (2014). https://doi.org/10.1186/2051-1426-2-S3-P26
- Pancreatic Cancer
- Tumor Infiltrate Lymphocyte
- Cellular Therapy
- Pancreatic Cancer Tissue
- Cytokine Cocktail